

Ref No. NLL/CS/2019-42

Dated: 25-05-2019

**1. National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block - G, Bandra  
Kurla Complex,  
Bandra (East), MUMBAI - 400 051.

**2. BSE Limited**  
Phiroze Jeejeebhoy Towers, Dalal  
Street,  
MUMBAI - 400 001.

## Sub: Audited Financial Results

**Ref.: Compliance under Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations & Disclosures Requirements) Regulations, 2015.**

Sir,

Pursuant to captioned Regulation, please find enclosed herewith a copy of the Audited Financial Results (Standalone and Consolidated) for the period ended on March 31, 2019, as approved by the Board of Directors in their meeting held on even dated i.e. May 25, 2019. A copy of the Auditor's Report is also enclosed herewith for your record please. The declaration that audit reports do not contain any modified opinion is also attached

Kindly acknowledge the receipt of the same and oblige.

**With Regards**

**For Nectar Lifesciences Limited**



**Dinesh Dua**

**Chief Executive Officer & Director**

**Encl: a.a.**

**CC: - Societe de la Bourse de Luxembourg S.A.**  
BP 165, L-2011 Luxembourg,  
Telephone: (00352) 47 79 38-1  
Fax: (00352) 47 32 98

# NECTAR LIFESCIENCES LIMITED


Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab -140507, Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email : cs@neclife.com,

Website : www.neclife.com, [CIN: L24232PB1995PLC016664]



## Statement of Financial Results for the Quarter and Year ended 31.03.2019 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			Year Ended		Year Ended	
		Standalone			Standalone		Consolidated	
		31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19	31-Mar-18
	Audited	Unaudited	Audited	Audited	Audited	Audited	Audited	
I	<b>Income from Operations</b>							
	Sales	88,021.74	82,021.24	68,280.71	311,492.29	209,231.93	311,285.78	209,304.37
	Less: GST Recovered	8,172.25	8,897.77	8,894.40	32,999.30	19,240.64	32,999.30	19,240.64
	<b>Revenue from Operations</b>	<b>79,849.49</b>	<b>73,123.47</b>	<b>59,386.31</b>	<b>278,492.99</b>	<b>189,991.29</b>	<b>278,286.48</b>	<b>190,063.73</b>
	Other operating Income	4.70	0.63	10.20	8.47	45.14	8.47	45.65
II	Other Income	166.24	153.36	126.51	595.53	558.44	595.53	558.44
III	<b>Total Income (I + II)</b>	<b>80,020.43</b>	<b>73,277.46</b>	<b>59,523.02</b>	<b>279,096.99</b>	<b>190,594.87</b>	<b>278,890.48</b>	<b>190,667.82</b>
IV	<b>Expenses</b>							
	(a) Cost of Materials consumed	67,468.28	57,199.38	49,945.16	222,531.73	138,163.89	222,531.73	138,164.63
	(b) Purchase of Stock in Trade	1,133.07	1,627.79	467.55	4,281.71	1,527.31	4,281.71	1,527.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4,195.55)	(144.11)	(4,168.87)	(4,698.55)	(3,043.22)	(5,042.79)	(2,990.87)
	(d) Excise Duty	-	-	69.02	-	2,438.15	-	2,438.15
	(e) Employee benefits expense	1,743.27	2,083.65	1,864.31	7,989.99	7,840.48	7,989.99	7,840.48
	(f) Finance costs	3,865.89	3,599.77	3,016.51	14,813.37	11,520.24	14,813.55	11,520.24
	(g) Depreciation and amortisation expense	1,454.15	1,687.76	1,616.51	6,325.74	6,430.88	6,325.74	6,430.88
	(h) Other expenses	6,268.51	5,789.75	6,097.69	21,997.79	19,460.56	22,108.54	19,468.73
	<b>Total Expenses (IV)</b>	<b>77,737.62</b>	<b>71,843.99</b>	<b>58,907.88</b>	<b>273,241.78</b>	<b>184,338.29</b>	<b>273,008.47</b>	<b>184,399.55</b>
V	<b>Profit before exceptional items and tax (III- IV)</b>	<b>2,282.81</b>	<b>1,433.47</b>	<b>615.14</b>	<b>5,855.21</b>	<b>6,256.58</b>	<b>5,882.01</b>	<b>6,268.27</b>
VI	Exceptional Items	-	-	-	-	-	-	-
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>2,282.81</b>	<b>1,433.47</b>	<b>615.14</b>	<b>5,855.21</b>	<b>6,256.58</b>	<b>5,882.01</b>	<b>6,268.27</b>
VIII	<b>Tax Expense (1) Current Tax</b>	<b>275.22</b>	<b>296.16</b>	<b>(97.11)</b>	<b>741.47</b>	<b>632.18</b>	<b>741.47</b>	<b>632.18</b>
	(2) Deferred Tax	266.88	5.72	323.19	380.56	408.92	380.56	408.92
IX	<b>Profit for the period from continuing operations (VII-VIII)</b>	<b>1,740.71</b>	<b>1,131.59</b>	<b>389.06</b>	<b>4,733.18</b>	<b>5,215.48</b>	<b>4,759.98</b>	<b>5,227.17</b>
	<b>Other Comprehensive Income</b>							
	<b>Items that will not be reclassified subsequently to profit or loss</b>							
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	2.60	-	109.66	2.60	109.66	2.60	109.66
	<b>Items that will be reclassified subsequently to profit or loss</b>							
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	22.51	(3.19)
	<b>Total Other Comprehensive Income, (Net of Tax)</b>	<b>2.60</b>	<b>-</b>	<b>109.66</b>	<b>2.60</b>	<b>109.66</b>	<b>25.11</b>	<b>106.47</b>
	<b>Total Comprehensive Income for the period</b>	<b>1,743.31</b>	<b>1,131.59</b>	<b>498.72</b>	<b>4,735.78</b>	<b>5,325.14</b>	<b>4,785.09</b>	<b>5,333.64</b>
X	<b>Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)</b>							
	a) Basic	0.78	0.50	0.17	2.11	2.33	2.12	2.33
	b) Diluted	0.78	0.50	0.17	2.11	2.33	2.12	2.33



**Nectar Lifesciences Limited**  
**Statement of Audited Assets and Liabilities**

(Rs. in Lakhs)



Sr.	Particulars	Standalone Audited Year ended		Consolidated Audited Year ended	
		March 31, 2019	March 31, 2018	March 31, 2019	March 31, 2018
	<b>Assets</b>				
1	<b>Non-current assets</b>				
	Property, plant and equipment	78,563.63	80,643.13	78,563.63	80,643.13
	Capital work-in-progress	9,955.03	9,978.55	9,955.03	9,978.55
	Investment property	-	-	-	-
	Goodwill	-	-	-	-
	Other intangible assets	3,918.16	4,592.40	3,918.16	4,592.40
	Intangible assets under development	-	-	-	-
	Biological assets other than bearer plants	-	-	-	-
	Investments accounted for using equity method	-	-	-	-
	Non-current investments	60.03	60.03	27.01	27.01
	Trade receivables, non-current	480.91	368.13	480.91	368.13
	Loans, non-current	-	-	-	-
	Other non-current financial assets	249.44	611.29	249.44	611.29
	Deferred tax assets (net)	-	-	-	-
	Other non-current assets	10,401.62	10,100.80	10,401.62	10,100.80
	<b>Total non-current assets</b>	<b>103,628.82</b>	<b>106,354.33</b>	<b>103,595.80</b>	<b>106,321.31</b>
2	<b>Current assets</b>				
	Inventories	91,452.74	85,943.48	91,796.98	85,943.48
	Current investments	50.54	50.95	50.54	50.95
	Trade receivables, current	56,137.94	61,211.55	55,873.19	61,196.96
	Cash and cash equivalents	2,057.97	890.83	2,132.73	931.08
	Bank balance other than cash and cash equivalents	-	-	-	-
	Loans, current	38.16	37.88	38.16	37.88
	Other current financial assets	10,190.59	11,223.15	10,190.59	11,223.15
	Current tax assets (net)	-	-	-	-
	Other current assets	6,820.79	6,677.20	6,820.79	6,677.20
	<b>Total current assets</b>	<b>166,748.73</b>	<b>166,035.04</b>	<b>166,902.98</b>	<b>166,060.70</b>
3	Non-current assets classified as held for sale	-	-	-	-
4	Regulatory deferral account debit balances and related deferred tax Assets	-	-	-	-
	<b>Total assets</b>	<b>270,377.55</b>	<b>272,389.37</b>	<b>270,498.78</b>	<b>272,382.01</b>
	<b>Equity and liabilities</b>				
1	<b>Equity</b>				
	<b>Equity attributable to owners of parent</b>				
	Equity share capital	2,242.61	2,242.61	2,242.61	2,242.61
	Other equity	108,221.10	103,620.29	108,273.50	103,623.38
	<b>Total equity attributable to owners of parent</b>	<b>110,463.71</b>	<b>105,862.90</b>	<b>110,516.11</b>	<b>105,865.99</b>
	Non controlling interest	-	-	-	-
	<b>Total equity</b>	<b>110,463.71</b>	<b>105,862.90</b>	<b>110,516.11</b>	<b>105,865.99</b>
2	<b>Liabilities</b>				
	<b>Non-current liabilities</b>				
	<b>Non-current financial liabilities</b>				
	Borrowings, non-current	16,558.95	22,007.62	16,558.95	22,007.62
	Trade payables, non-current	-	-	-	-
	(A) total outstanding dues of micro enterprises and small enterprises;	-	-	-	-
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	-	-	-	-
	Other non-current financial liabilities	1,192.54	1,756.45	1,192.54	1,756.45
	Provisions, non-current	936.30	906.88	936.30	906.88
	Deferred tax liabilities (net)	11,215.81	10,833.85	11,217.29	10,823.39
	Deferred government grants, Non-current	-	-	-	-
	Other non-current liabilities	87.08	89.58	87.08	89.58
	<b>Total non-current liabilities</b>	<b>29,990.68</b>	<b>35,594.38</b>	<b>29,992.16</b>	<b>35,583.92</b>
	<b>Current liabilities</b>				
	<b>Current financial liabilities</b>				
	Borrowings, current	63,596.86	63,408.26	63,596.86	63,408.26
	Trade payables, current	-	-	-	-
	(A) total outstanding dues of micro enterprises and small enterprises;	444.26	296.71	444.26	296.71
	(B) total outstanding dues of creditors other than micro enterprises and small enterprises	52,633.86	53,645.67	52,701.21	53,645.67
	Other current financial liabilities	11,299.44	11,233.70	11,299.44	11,233.70
	Other current liabilities	962.25	1,106.64	962.25	1,106.64
	Provisions, current	85.78	48.81	85.78	48.81
	Current tax liabilities (Net)	900.71	1,192.30	900.71	1,192.31
	Deferred government grants, Current	-	-	-	-
	<b>Total current liabilities</b>	<b>129,923.16</b>	<b>130,932.09</b>	<b>129,990.51</b>	<b>130,932.10</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	-	-	-	-
4	Regulatory deferral account credit balances and related deferred tax liability	-	-	-	-
	<b>Total liabilities</b>	<b>159,913.84</b>	<b>166,526.47</b>	<b>159,982.67</b>	<b>166,516.02</b>
	<b>Total equity and liabilities</b>	<b>270,377.55</b>	<b>272,389.37</b>	<b>270,498.78</b>	<b>272,382.01</b>



*[Handwritten signature]*















